A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting

Phase 1

INCA33890A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Sponsor:

Incyte Corporation

Code:

NCT05836324

Conditions

Solid Tumors

Advanced Solid Tumors

Metastatic Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

INCA33890

bevacizumab

FOLFIRI

FOLFOX

Cetuximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-20. This information was provided to ClinicalTrials.gov by Incyte Corporation on 2025-12-18.